Image pharmaphorum Editor Oncology Beyond traditional cancer treatment: Can we confront unmet n... Surgery, chemotherapy, radiotherapy, and immunotherapy are designed to kill cancer, but what if we could control cancer? R&D The growth of radiotherapeutics: Addressing supply chain com... Players, current and emergent, should prepare for complexities in the supply chain as radiotherapeutics continues to rise. Sales & Marketing Sponsored Go slow to go fast: Setting a content transformation journey... Pharma marketing is evolving and it’s evolving quickly. How can organisations successfully ride the wave of this transformation? Digital Frontiers Health 2024: Day Two We are back for Day Two of Frontiers Health, coming to you live from the heart of Berlin! Load more results
Oncology Beyond traditional cancer treatment: Can we confront unmet n... Surgery, chemotherapy, radiotherapy, and immunotherapy are designed to kill cancer, but what if we could control cancer?
R&D The growth of radiotherapeutics: Addressing supply chain com... Players, current and emergent, should prepare for complexities in the supply chain as radiotherapeutics continues to rise.
Sales & Marketing Sponsored Go slow to go fast: Setting a content transformation journey... Pharma marketing is evolving and it’s evolving quickly. How can organisations successfully ride the wave of this transformation?
Digital Frontiers Health 2024: Day Two We are back for Day Two of Frontiers Health, coming to you live from the heart of Berlin!
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
